Constrictive pericarditis following inactivated virus COVID-19 vaccine: a case report with review of the literature

Hajsadeghi, Shokoufeh; Mesgarha, Milad Gholizadeh; Shahrbabaki, Elahe Saberi; Pishgahi, Maryam; Azar, Aria Ebadi Fard; Mohammad, Arash Pour

doi:10.1016/j.radcr.2022.07.021

Cited by 9 publications

(9 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 33 34 35 36 37 38 39 40 41 42 43 ] The pericardial disease primarily associated with these situations is known to be acute pericarditis. [ 44 45 ] However, we found >10 case reports of CP following the diagnosis of COVID-19 or the administration of mRNA-vaccine,[ 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 ] with a temporal relationship ranging from 4 days to 7 months, and without predilection for age groups. All cases reported an effusive–CP, suggesting an acute-on-chronic or subacute mechanism, except for two cases,[ 56 57 ] in which a transient constriction was described.…”

Section: N Oninvasive D Iagnosis Of ...mentioning

confidence: 97%

“…[ 44 45 ] However, we found >10 case reports of CP following the diagnosis of COVID-19 or the administration of mRNA-vaccine,[ 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 ] with a temporal relationship ranging from 4 days to 7 months, and without predilection for age groups. All cases reported an effusive–CP, suggesting an acute-on-chronic or subacute mechanism, except for two cases,[ 56 57 ] in which a transient constriction was described. In more than half of cases,[ 46 47 48 53 55 56 57 ] a cardiac comorbidity was present, with a predominance of arterial hypertension.…”

Section: N Oninvasive D Iagnosis Of ...mentioning

confidence: 99%

See 1 more Smart Citation

Constrictive Pericarditis: An Update on Noninvasive Multimodal Diagnosis

Restelli,

Carerj,

Bella

et al. 2023

Journal of Cardiovascular Echography

View full text Add to dashboard Cite

Constrictive pericarditis (CP) is a rare condition that can affect the pericardium after every pericardial disease process and has been described even after SARS-CoV-2 infection or vaccine. In CP, the affected pericardium, usually the inner layer, is noncompliant, constraining the heart to a fixed maximum volume and impairing the diastolic function. This leads to several clinical features, that, however, can be pleomorphic. In its difficult diagnostic workup, noninvasive multimodal imaging plays a central role, providing important morphological and functional data, like the enhanced ventricular interdependence and the dissociation between intrathoracic and intracardiac pressures. An early and proper diagnosis is crucial to set an appropriate therapy, changing the prognosis of patients affected by CP. In this review, we cover in detail the main elements of each imaging technique, after a reminder of pathophysiology useful for understanding the diagnostic findings.

show abstract

Section: N Oninvasive D Iagnosis Of ...mentioning

confidence: 97%

Section: N Oninvasive D Iagnosis Of ...mentioning

confidence: 99%

Constrictive Pericarditis: An Update on Noninvasive Multimodal Diagnosis

Restelli,

Carerj,

Bella

et al. 2023

Journal of Cardiovascular Echography

View full text Add to dashboard Cite

show abstract

“…The COVID-19 pandemic engendered mayhem of medical concerns. Despite the early picture of respiratory involvement of the disease, given the rapid dissemination of the virus, the evidence of various organs' involvement soon became populated in medical literature (1)(2)(3). Skin as a mirror to internal events in the body, was among the earliest non-respiratory organs raising concern over non-typical manifestations of the disease (4).…”

Section: Introductionmentioning

confidence: 99%

A case series of interesting mucocutaneous presentations in COVID-19 infection or post COVID-19 vaccination confirmed by biopsy and histopathologic assessment

Mohammad

Noroozi

Mesgarha

et al. 2023

Preprint

View full text Add to dashboard Cite

Mucocutaneous complications or adverse events due to SARS-CoV-2 infection or vaccination have been well-delineated in the literature, respectively. Most eruptions are considered to be mild and self-limiting; however, for the atypical cases which have a tentative clinical diagnosis, performing a biopsy and histopathological assessment is pivotal to confirm the diagnosis and subsequently prescribe a more tailored treatment. Despite the diverse reporting of such incidents globally, the rate of biopsied cases is restricted to less than 15% in most studies. This case series elucidates 20 patients referred to the tertiary dermatology clinic, including 14 COVID-19 infection-related eruptions such as Lichen Planus (LP), Cutaneous vasculitis, Pityriasis rosea (PR), Discoid lupus erythematosus, Guttate psoriasis, Sarcoidosis, Raynaud’s phenomenon, non-specific lesions resembling genital warts, Beau’s line and one severe case of purpura fulminans with a promising outcome. Moreover, we presented 6 vaccine-induced cases comprising LP, Urticarial vasculitis, PR, Parapsoriasis, and Localized Morphea. The diagnosis of all cases has been proven by histopathological evaluation. We included pertaining anamnesis details of each patient together with vivid classifying images to pinpoint the morphologic features of each condition. In line with our previous studies, the vaccine-induced eruptions were less severe compared to infection-related complications of COVID-19 and are mostly controllable by antihistamines and corticosteroids administration. Therefore, reporting such events should not hinder COVID-19 vaccination in the general population.

show abstract

“…[6][7][8][9] Contrary to mild and moderate local or systemic adverse effects that may occur after vaccination, intense medical consequences are uncommon. 2,10,11 Several case series, nevertheless, revealed hematological problems such as immune thrombocytopenic purpura (ITP) induced by vaccination. 8,12 ITP is an autoimmune disease of platelet destruction resulting in a platelet count below 100 000 per cubic millimeter and has an incidence of two to five cases per 100 000 person-years.…”

Section: Introductionmentioning

confidence: 99%

“…However, the safety and adverse effects of the COVID‐19 vaccines have been a major public concern, resulting in vaccine hesitancy that necessitates ongoing and comprehensive observation and research 6–9 . Contrary to mild and moderate local or systemic adverse effects that may occur after vaccination, intense medical consequences are uncommon 2,10,11 . Several case series, nevertheless, revealed hematological problems such as immune thrombocytopenic purpura (ITP) induced by vaccination 8,12 …”

Section: Introductionmentioning

confidence: 99%

Immune thrombocytopenic purpura secondary to COVID‐19 vaccination: A systematic review

Bidari

Asgarian

Mohammad

et al. 2022

European J of Haematology

Self Cite

View full text Add to dashboard Cite

Introduction This systematic review aimed to retrieve patients diagnosed with de novo immune thrombocytopenic purpura (ITP) after COVID‐19 immunization to determine their epidemiological characteristics, clinical course, therapeutic strategies, and outcome. Materials and Methods We conducted the review using four major databases, comprising PubMed, Scopus, Web of Science, and the Cochrane library, until April 2022. A systematic search was performed in duplicate to access eligible articles in English. Furthermore, a manual search was applied to the chosen papers' references to enhance the search sensitivity. Data were extracted and analyzed with the SPSS 20.1 software. Results A total of 77 patients with de novo COVID‐19 vaccine‐associated ITP were identified from 41 studies, including 31 case reports and 10 case series. The median age of patients who developed COVID‐19 vaccine‐associated ITP was 54 years (IQR 36–72 years). The mRNA‐based COVID‐19 vaccines, including BNT16B2b2 and mRNA‐1273, were most implicated (75.4%). Those were followed by the adenovirus vector‐based vaccines, inclusive of ChAdOx1 nCoV‐19 and vAd26.COV2.S. No report was found relating ITP to other COVID‐19 vaccines. Most cases (79.2%) developed ITP after the first dose of COVID‐19 vaccination. 75% of the patients developed ITP within 12 days of vaccination, indicating a shorter lag time compared to ITP after routine childhood vaccinations. Sixty‐seven patients (87%) patients were hospitalized. The management pattern was similar to primary ITP, and systemic glucocorticoids, IVIg, or both were the basis of the treatment in most patients. Most patients achieved therapeutic goals; only two individuals required a secondary admission, and one patient who presented with intracranial hemorrhage died of the complication. Conclusions De novo ITP is a rare complication of COVID‐19 vaccination, and corresponding reports belong to mRNA‐based and adenovirus vector‐based vaccines, in order of frequency. This frequency pattern may be related to the scale of administration of individual vaccines and their potency in inducing autoimmunity. The more the COVID‐19 vaccine is potent to induce antigenic challenge, the shorter the lag time would be. Most patients had a benign course and responded to typical treatments of primary ITP.

show abstract

Constrictive pericarditis following inactivated virus COVID-19 vaccine: a case report with review of the literature

Cited by 9 publications

References 16 publications

Constrictive Pericarditis: An Update on Noninvasive Multimodal Diagnosis

Constrictive Pericarditis: An Update on Noninvasive Multimodal Diagnosis

A case series of interesting mucocutaneous presentations in COVID-19 infection or post COVID-19 vaccination confirmed by biopsy and histopathologic assessment

Immune thrombocytopenic purpura secondary to COVID‐19 vaccination: A systematic review

Contact Info

Product

Resources

About